SEC Form 4 · accession 0001209191-18-059370
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly J Popovits
Officer — President and CEO · Director
Period of report
Nov 15, 2018
Accepted (ET)
Nov 19, 2018 · 9:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 15, 2018 | M | 25,000 | $22.98 | A | 201,982 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F3 | Nov 15, 2018 | S | 5,000 | $74.774 | D | 196,982 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F4 | Nov 15, 2018 | S | 1,925 | $75.7818 | D | 195,057 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F5 | Nov 15, 2018 | S | 5,138 | $76.8921 | D | 189,919 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F6 | Nov 15, 2018 | S | 2,854 | $77.5574 | D | 187,065 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F7 | Nov 15, 2018 | S | 10,083 | $78.6859 | D | 176,982 | I | Held by the Popovits 2010 Trust |
| Common Stock | Nov 16, 2018 | M | 15,000 | $22.98 | A | 191,982 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F8 | Nov 16, 2018 | S | 8,661 | $76.309 | D | 183,321 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F9 | Nov 16, 2018 | S | 4,939 | $77.1035 | D | 178,382 | I | Held by the Popovits 2010 Trust |
| Common StockF1,F2,F10 | Nov 16, 2018 | S | 1,400 | $77.905 | D | 176,982 | I | Held by the Popovits 2010 Trust |
| Common StockF11 | holding | — | — | — | 59,517 | D | ||
| Common Stock | holding | — | — | — | 12,298 | I | Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F12 | $22.98 | Nov 15, 2018 | M | 25,000 | D | — | Jan 27, 2021 | Common Stock | 25,000 | 15,000 | D |
| Employee Stock Option (right to buy)F12 | $22.98 | Nov 16, 2018 | M | 15,000 | D | — | Jan 27, 2021 | Common Stock | 15,000 | 0 | D |
Explanation of responses
- F1These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 14, 2018.
- F10Represents weighted average sale price. Actual sale prices ranged from $77.67 to $78.06.
- F11Includes an aggregate of 51,204 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F12The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.
- F2Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F3Represents weighted average sale price. Actual sale prices ranged from $74.21 to $75.15.
- F4Represents weighted average sale price. Actual sale prices ranged from $75.265 to $76.25.
- F5Represents weighted average sale price. Actual sale prices ranged from $76.27 to $77.22.
- F6Represents weighted average sale price. Actual sale prices ranged from $77.28 to $78.23.
- F7Represents weighted average sale price. Actual sale prices ranged from $78.31 to $79.22.
- F8Represents weighted average sale price. Actual sale prices ranged from $75.60 to $76.58.
- F9Represents weighted average sale price. Actual sale prices ranged from $76.61 to $77.60.